Renal angiomyolipomata

John Bissler, J. Chris Kingswood

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Renal angiomyolipomata can exist as an imaging curiosity or represent a life-threatening condition. There are likely over 10 million people world-wide who have a renal angiomyolipomata and approximately one tenth of these people also have tuberous sclerosis complex. The optimum treatment of angiomyolipomata is focused on sparing renal tissue and has included no intervention, both total and partial nephrectomy, and embolization. As basic science investigation into the biology of angiomyolipomata progresses, there is even hope for successful drug therapy. Because these renal lesions can be associated with other organ system dysfunction, a number of medical specialists become involved in the care of affected patients. The purpose of this article is to update the nephrologist on the molecular understanding of renal angiomyolipomata and for the possibilities of pharmacologic therapy in the future.

Original languageEnglish (US)
Pages (from-to)924-934
Number of pages11
JournalKidney International
Volume66
Issue number3
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Angiomyolipoma
Kidney
Hope
Exploratory Behavior
Tuberous Sclerosis
Nephrectomy
Patient Care
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Renal angiomyolipomata. / Bissler, John; Kingswood, J. Chris.

In: Kidney International, Vol. 66, No. 3, 01.01.2004, p. 924-934.

Research output: Contribution to journalArticle

Bissler, John ; Kingswood, J. Chris. / Renal angiomyolipomata. In: Kidney International. 2004 ; Vol. 66, No. 3. pp. 924-934.
@article{821beb2912eb4fb988b84870e04ce730,
title = "Renal angiomyolipomata",
abstract = "Renal angiomyolipomata can exist as an imaging curiosity or represent a life-threatening condition. There are likely over 10 million people world-wide who have a renal angiomyolipomata and approximately one tenth of these people also have tuberous sclerosis complex. The optimum treatment of angiomyolipomata is focused on sparing renal tissue and has included no intervention, both total and partial nephrectomy, and embolization. As basic science investigation into the biology of angiomyolipomata progresses, there is even hope for successful drug therapy. Because these renal lesions can be associated with other organ system dysfunction, a number of medical specialists become involved in the care of affected patients. The purpose of this article is to update the nephrologist on the molecular understanding of renal angiomyolipomata and for the possibilities of pharmacologic therapy in the future.",
author = "John Bissler and Kingswood, {J. Chris}",
year = "2004",
month = "1",
day = "1",
doi = "10.1111/j.1523-1755.2004.00838.x",
language = "English (US)",
volume = "66",
pages = "924--934",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Renal angiomyolipomata

AU - Bissler, John

AU - Kingswood, J. Chris

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Renal angiomyolipomata can exist as an imaging curiosity or represent a life-threatening condition. There are likely over 10 million people world-wide who have a renal angiomyolipomata and approximately one tenth of these people also have tuberous sclerosis complex. The optimum treatment of angiomyolipomata is focused on sparing renal tissue and has included no intervention, both total and partial nephrectomy, and embolization. As basic science investigation into the biology of angiomyolipomata progresses, there is even hope for successful drug therapy. Because these renal lesions can be associated with other organ system dysfunction, a number of medical specialists become involved in the care of affected patients. The purpose of this article is to update the nephrologist on the molecular understanding of renal angiomyolipomata and for the possibilities of pharmacologic therapy in the future.

AB - Renal angiomyolipomata can exist as an imaging curiosity or represent a life-threatening condition. There are likely over 10 million people world-wide who have a renal angiomyolipomata and approximately one tenth of these people also have tuberous sclerosis complex. The optimum treatment of angiomyolipomata is focused on sparing renal tissue and has included no intervention, both total and partial nephrectomy, and embolization. As basic science investigation into the biology of angiomyolipomata progresses, there is even hope for successful drug therapy. Because these renal lesions can be associated with other organ system dysfunction, a number of medical specialists become involved in the care of affected patients. The purpose of this article is to update the nephrologist on the molecular understanding of renal angiomyolipomata and for the possibilities of pharmacologic therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=4344669265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344669265&partnerID=8YFLogxK

U2 - 10.1111/j.1523-1755.2004.00838.x

DO - 10.1111/j.1523-1755.2004.00838.x

M3 - Article

VL - 66

SP - 924

EP - 934

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -